Descrizione

According to NIH, autoimmune disorders are conditions in which the body’s immune system mistakenly attacks and destroys healthy tissues of the body by perceiving them as foreign bodies. The majority of autoimmune disorders cause inflammation of affected parts of the body. The most commonly occurring autoimmune disorder include psoriasis, systemic lupus erythematosus, and rheumatoid arthritis, among others. The global autoimmune disorder drugs market in terms of revenue is set to grow by US$ 40 miliardi durante 2021-2027, crescendo ad un tasso di crescita annuale composto (CAGR) Di 9.8% durante il periodo di previsione, secondo la società di dati e analisi StrategyHelix. Growth in the geriatric population, increasing prevalence of autoimmune disorders, the rise in technological advancements for the diagnosis of autoimmune diseases are expected to boost the market growth in the coming years.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2017-2020 e previsione a 2027 covering key market aspects like sales value for autoimmune disorder drugs. The global autoimmune disorder drugs market is segmented on the basis of type, indication, regione. Per tipo, it is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), and Immunosuppressant drugs. The NSAIDs segment held the largest market share in 2020. By indication, the autoimmune disorder drugs market is divided into rheumatoid arthritis, systemic lupus erythematosus, psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, tipo 1 diabetes, e altri. The rheumatoid arthritis segment accounted for the largest market share in 2020. Based on region, the autoimmune disorder drugs market is divided into North America, Asia Pacifico, Europa, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb (BMS), Johnson & Johnson, Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Vertex Pharmaceuticals Inc..

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the autoimmune disorder drugs market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Tipo: nonsteroidal anti-inflammatory drugs (NSAIDs), and Immunosuppressant drugs
Indication: rheumatoid arthritis, systemic lupus erythematosus, psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, tipo 1 diabetes, e altri
Regione: Nord America, Asia Pacifico, Europa, and Rest of the World (ROW)
Anni considerati: la presente relazione copre il periodo 2017 A 2027

Principali vantaggi per gli stakeholder

Get a comprehensive picture of the global autoimmune disorder drugs market
Individuare i settori in crescita e le tendenze per gli investimenti
Understand what the future of the global autoimmune disorder drugs market looks like
Identificare il panorama competitivo e la finestra di opportunità

Sommario

1. Definizione del mercato
2. Metodologia di ricerca
3. Dati di mercato & Veduta
3.1 Valore di mercato
3.2 Previsione del valore di mercato
4. Autoimmune Disorder Drugs Market by Type
4.1 Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
4.2 Immunosuppressant Drugs
5. Autoimmune Disorder Drugs Market by Indication
5.1 Rheumatoid Arthritis
5.2 Systemic Lupus Erythematosus
5.3 Psoriasis/Psoriatic Arthritis
5.4 Multiple Sclerosis
5.5 Inflammatory Bowel Disease
5.6 Tipo 1 Diabetes
5.7 Altri
6. Autoimmune Disorder Drugs Market by Region
6.1 Nord America
6.2 Asia Pacifico
6.3 Europa
6.4 Rest Of The World (Row)
7. Profili aziendali
7.1 AbbVie Inc.
7.2 Amgen Inc.
7.3 AstraZeneca plc
7.4 Bayer AG
7.5 Bristol Myers Squibb (BMS)
7.6 Johnson & Johnson
7.7 Mylan N.V.
7.8 Novartis AG
7.9 Pfizer Inc.
7.10 Roche Holding AG
7.11 Vertex Pharmaceuticals, Inc.
8. Appendice
8.1 Informazioni su StrategyHelix
8.2 Disclaimer